TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 13418
Drug: MIF-1 75
Normalized name: Immunoglobulin g1-kappa, anti-(homo sapiens mif (macrophage migration inhibitory factor, glycosylation-inhibiting factor, glif, gif)), homo sapiens monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIF-1 75 mg per day
Study: 13418
Drug: MIF-1 750
Normalized name: Immunoglobulin g1-kappa, anti-(homo sapiens mif (macrophage migration inhibitory factor, glycosylation-inhibiting factor, glif, gif)), homo sapiens monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIF-1 750 mg per day
Study: 13418
Drug: LHRH 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH 700 mug or saline once daily for 3 consecutive days per week
Study: 13418
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of LHRH in a single-blinded study
Study: 31647470
Drug: 23vPPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23vPPV vaccine
Study: 23936304
Drug: PCT guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT guided treatment
Study: 19855285
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy (IT)
Study: 11280679
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (500 microg Se daily for 5 days)
Study: 3350203
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg aspirin daily
Study: 3350203
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg dipyridamole three times daily
Study: 30767637
Drug: Botanically-enriched topical
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Botanically-enriched topical salve (BES)
Study: 28225483
Drug: MTHFR genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTHFR genotype (CC/CT)
Study: 21575959
Drug: Oral tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tadalafil 20 mg plus low dose intracavernous injection of vasoactive agents (15 mg papaverine plus 20 mg tadalafil)
Study: 21575959
Drug: Oral tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tadalafil 20 mg
Study: 21575959
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection mode (30 to 60 mg papaverine)
Study: 20015432
Drug: Cefradine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefradine (oral administration)
Study: 16413010
Drug: Warfarin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (mean daily dose 3.11±1.62 mg)
Study: 14652518
Drug: CONFOR‐Med mattress/cushion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONFOR‐Med mattress/cushion combination
Study: 14652518
Drug: Standard mattress/cushion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard mattress/cushion combination
Study: 11126272
Drug: iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iloprost infusion (1 ng/kg per minute) for 24 h
Study: 19136144
Drug: Long-acting opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting opioid analgesics
Study: 11693062
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha as maintenance treatment
Study: 11693062
Drug: Cyclically alternating
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclically alternating interferon alpha and dexamethasone treatment
Study: 8434322
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of standard-dose chymopapain (4,000 units)
Study: 8434322
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of low-dose chymopapain (2,000 units)
Study: 26817117
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of NASH (Ursodeoxycholic acid 15 mg/kg once a day, Atorvastatin 20 mg at night, Vitamin E 800 IU/day for 12 months)
Study: 26817117
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/day in addition to standard treatment for 12 months
Study: 18276852
Drug: NK1R antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NK1R antagonist (LY686017)
Study: 16982493
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) > 1.0 mg/dl
Study: 11088095
Drug: 17‐beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17‐beta estradiol with 0.5 mg of norethindrone acetate
Study: 11088095
Drug: 17‐beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17‐beta estradiol with 0.25 mg of norethindrone acetate
Study: 16482084
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of 17‐beta estradiol
Study: 27071140
Drug: e-PRP injection
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-PRP injection
Study: 25398137
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Vacc-4x
Study: 25398137
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Vacc-4x
Study: 25398137
Drug: Vacc-4x (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacc-4x (all doses)
Study: 24765899
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) 0.1 mg
Study: 23872462
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIA) with ropivacaine 300 mg + ketorolac 30 mg + epinephrine 0.5 mg
Study: 20374662
Drug: Sports chiropractic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports chiropractic manual therapy intervention
Study: 18491137
Drug: Maximum androgen
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum androgen blockade (MAB) with bicalutamide (Casodex) 80 mg plus LHRHa
Study: 18491137
Drug: LHRHa monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRHa monotherapy
Study: 12563210
Drug: Duplex ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duplex ultrasound scan with ultrasound scan contrast agent
Study: 2862087
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin supplement (ultralente insulin)
Study: 28135023
Drug: Paracetamol only
Normalized name: Paracetamol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol only
Study: 29017585
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of paracetamol and ibuprofen
Study: 30803141
Drug: Intra-oral camera
Normalized name: Calmera Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-oral camera (IOC)
Study: 14628599
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg once a day for 3 days
Study: 14628599
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment with indwelling catheter and oral antibiotics)
Study: 10369847
Drug: Ibutilide pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide pretreatment (1 mg)
Study: 1782776
Drug: Topical autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical autologous plasma fibronectin, given 5 times per day for 11 weeks.
Study: 19574176
Drug: Calcium (1,000
Normalized name: calcium carbonate 390 mg calcium (1,000 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1,000 mg) and Vitamin D (400 IU)
Study: 19574176
Drug: Calcium (1,000
Normalized name: calcium carbonate 390 mg calcium (1,000 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1,000 mg) and Vitamin D (400 IU) plus Metformin (1,500 mg)
Study: 30518693
Drug: Metformin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,500 mg)
Study: 17291216
Drug: MMF stop
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF stop group (reduced and then stopped MMF dose)
Study: 17291216
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued tacrolimus/MMF/steroids triple regimen)
Study: 12466028
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) 400 mg/d intramuscularly
Study: 12466028
Drug: Imipramine (IMI)
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine (IMI) 150 mg/d orally
Study: 8567842
Drug: Two layer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two layer Percoll gradient (1 ml semen layered on 36 and 81% Percoll gradient)
Study: 8567842
Drug: SpermPrep II
Approvals — FDA: no, EMA: no, PMDA: no
Description: SpermPrep II method (1 ml semen run through SpermPrep II column)
Study: 7306434
Drug: Terbutaline (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (2.5 and 5 mg)
Study: 7306434
Drug: Clenbuterol (larger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenbuterol (larger doses)
Study: 15491244
Drug: Citalopram plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram plus mirtazapine (15-30 mg/day)
Study: 9157451
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily 40 mg prednisolon i.v., 2 x theophylline i.v., 3 x inhalation of beta 2+ parasympathicolytic)
Study: 29024499
Drug: Men's Club
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men's Club intervention (5-hour interactive educational intervention + weekly text message reminders for 6 weeks)
Study: 24612659
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with solifenacin 5 mg and mirabegron (various doses)
Study: 24612659
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg monotherapy
Study: 23007324
Drug: AR-GG27® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-GG27® cream (sorbityl furfural palmitate)
Study: 20398559
Drug: Drug intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug intervention group (hydrochlorothiazide, nitrendipine, and captopril)
Study: 20398559
Drug: Drug intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug intervention group
Study: 10447620
Drug: Conventional Pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Pain Therapy (CPT) with tramadol (oral or intramuscularly) or piritramid intravenously
Study: 23631443
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of metformin and RE
Study: 17284576
Drug: Stavudine, 30-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine, 30-40 mg, twice a day for 1 month
Study: 12823645
Drug: Raloxifene 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 150 mg day‐1
Study: 12823645
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogen (CEE) 0.625 mg day‐1
Study: 10195186
Drug: Vagus nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus nerve stimulation administered after learning
Study: 8585003
Drug: Control cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cycle without injection
Study: 304984
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of dextran 60 intraoperatively (group A)
Study: 304984
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml dextran 60 on days 1 to 5 after operation (group B)
Study: 18547128
Drug: IR methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR methylphenidate (Rubifen) 52.1 mg (SD = 13.8 mg) three times daily for 3 months
Study: 18547128
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (Concerta) 57.9 mg (SD = 16.5 mg) once daily after switch
Study: 16177676
Drug: Carvedilol treatment
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol treatment (Group I, n=32)
Study: 16177676
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Group II, n=27)
Study: 11901392
Drug: Cortisone injection
Normalized name: hydrocortisone Injection
DrugBank: Cortisone (DB14681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisone injection into the tendon sheath
Study: 7768585
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium 10 mg
Study: 7768585
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium 100 mg
Study: 7768585
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium 150 mg
Study: 7768585
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate 20 mg
Study: 2186523
Drug: TD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD group (Aza added to continued low-dose CsA and prednisone)
Study: 21323289
Drug: Ropivacaine 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 24 mg plus morphine 8 mg (group R+M)
Study: 21323289
Drug: Ropivacaine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 40 mg (group R)
Study: 21323289
Drug: Ropivacaine 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 36 mg plus ketoprofen 100 mg (group R+K)
Study: 10740573
Drug: Larva therapy
Normalized name: Bombyx mori larva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larva therapy (LT)
Study: 1441873
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 5 mg (Group 2)
Study: 22531485
Drug: 5% Lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Lidocaine patch
Study: 26484869
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment plus Contingency Management (CBT + CM)
Study: 12572358
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Ca supplementation per day
Study: 8667133
Drug: Saline group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group, irrigation with 2 cc of 0.85% saline
Study: 8667133
Drug: Tetracycline group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline group, irrigation with 2 cc of aqueous tetracycline HCl, 50 mg/ml (5%)
Study: 8667133
Drug: Chlorhexidine group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine group, irrigation with 2 cc of chlorhexidine
Study: 30992093
Drug: ACT-based lifestyle
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-based lifestyle modification treatment
Study: 28629828
Drug: Prosthesis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosthesis treatment
Study: 26519020
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (walking and running for 25 minutes twice/week for 10 weeks at intensity corresponding to individual's ventilatory threshold)
Study: 9256222
Drug: Abciximab bolus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab bolus plus infusion
Study: 12854176
Drug: Heparin/low molecular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin/low molecular weight heparin (LMWH) treatment
Study: 10363737
Drug: ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac tromethamine 0.5% ophthalmic solution
Study: 8489449
Drug: PhXA41 (0.006%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhXA41 (0.006% solution, approximately 2 micrograms per treatment)
Study: 2812914
Drug: Ceftriaxone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (80 mg/kg body weight, intramuscularly, once daily for 5 days)
Study: 2812914
Drug: Chloramphenicol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (50 to 100 mg/kg body weight, orally, divided into 4 doses for 3 weeks)
Study: 29574484
Drug: Solifenacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5 mg, once daily)
Study: 23187965
Drug: Teduglutide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide (10 mg, subcutaneously administered)
Study: 17012860
Drug: DTPw‐HBV/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw‐HBV/Hib vaccine
Study: 11240031
Drug: Circulating levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating levels of soluble forms of adhesion molecules (sICAM-1 and sVCAM-1)
Study: 9210689
Drug: Cefdinir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir (300 mg twice daily for 10 days)
Study: 1656740
Drug: Cefaclor (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (500 mg three times daily for 10 days)
Study: 3614956
Drug: 0.11 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.11 mg/kg diazepam
Study: 3614956
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diazepam and fentanyl doses
Study: 29268206
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT) 10000lx
Study: 27282265
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group)
Study: 27282265
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg esomeprazole daily (monotherapy group)
Study: 20093623
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (RW) 100 mL daily for 3 weeks
Study: 20093623
Drug: Water (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (100 mL) daily for 3 weeks
Study: 20093623
Drug: Beer (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beer (250 mL) daily for 3 weeks
Study: 20093623
Drug: Vodka (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vodka (30 mL) daily for 3 weeks
Study: 16195036
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity and ibuprofen (combination)
Study: 9863122
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine of replenishing Qi and nourishing Yin (RQNY) combined with a small dosage of Tapazol
Study: 9863122
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (TCM + Tapazol)
Study: 9863122
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Tapazol)
Study: 3815397
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) 10 mg
Study: 3815397
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) 5 mg
Study: 3815397
Drug: Oral (PO)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (PO) 10 mg
Study: 3815397
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) 5 mg
Study: 23764005
Drug: Tinzaparin 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin 175 IU/kg once daily for 6 months
Study: 23764005
Drug: Initial tinzaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial tinzaparin 175 IU/kg once daily for 5-10 days and dose-adjusted warfarin (target INR 2.0-3.0) for 6 months
Study: 19265308
Drug: Hand acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand acupuncture therapy (including hand acupuncture and press-pellets based on corresponding points)
Study: 16325440
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of racemic albuterol from dry powder inhalers
Study: 11726410
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 4 mg
Study: 11726410
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 6 mg
Study: 9743164
Drug: Maxair Autohaler
Normalized name: Maxair Autohaler
DrugBank: Pirbuterol (DB01291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maxair Autohaler (1,200 microg pirbuterol) plus saline solution by nebulizer
Study: 9743164
Drug: Placebo by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by Autohaler plus 2,500 microg albuterol via nebulizer